H.C. Wainwright raises Relay Therapeutics stock price target to $25

H.C. Wainwright raised its Relay Therapeutics price target to $25 from $19 and increased its probability of approval for zovegalisib to 75% from 65%, citing encouraging Phase 1 ReDiscover data. The triplet regimen of zovegalisib, atirmociclib and endocrine therapy produced a 44% objective response rate in 34 heavily pretreated patients, supporting a Phase 3 move in first-line PI3Kα-positive HR+/HER2- metastatic breast cancer. Multiple analysts have also recently lifted targets, reinforcing improving sentiment around the pipeline.

Analysis

The market is increasingly valuing Relay as a de-risked platform story rather than a single-asset binary, and that matters because the next leg is likely to be driven by trial-design credibility, not just response-rate optics. A 44% ORR in a heavily pretreated population is enough to keep momentum going, but the more important second-order effect is that management now has a clearer path to a registrational debate in first line, where even modest clinical differentiation can command a large valuation uplift for a small-cap biotech.

The competitive read-through is more interesting than the headline. If first-line standards are still posting materially higher ORR, Relay does not need to win on peak efficacy alone; it needs to show durability, tolerability, and a biomarker-defined niche that reduces discontinuation and post-progression costs. That creates a real channel for collaboration optionality as well: large oncology players with CDK4/6 or endocrine franchises may prefer to partner or compete via combination ecosystems rather than build internally, which supports both Relay and Pfizer strategic relevance.

The near-term risk is that the stock has already priced a lot of the “good data, higher PT” narrative, so a flat or messy Phase 3 launch plan could trigger a sharp multiple reset even if the science remains intact. Over the next 1-3 months, the setup is more sentiment- and positioning-driven than fundamentals-driven; over 6-12 months, readouts and patient selection will decide whether this becomes a platform franchise or another biotech with a good phase 1 story. The contrarian view is that the recent analyst target raises may be extrapolating from a small, selected dataset and understating the bar for first-line adoption, where payers and oncologists care more about durability and safety than an isolated ORR print.

Key Decisions for Investors

• Stay tactically long RLAY only via defined-risk structures: buy 3-6 month call spreads or a small cash equity position on 10-15% pullbacks, targeting a catalyst window into Phase 3 planning; upside remains meaningful, but the stock is vulnerable to sharp giveback on any trial-design disappointment.
• Short-term traders: consider selling covered calls against existing RLAY longs into strength to monetize elevated implied volatility; the risk/reward favors harvesting premium while the story awaits a true de-risking event.
• Pair trade: long RLAY / short a basket of later-stage oncology names with similar market caps but less fresh data momentum, to isolate the valuation re-rating from sector beta; this works best over the next 1-2 quarters if the upgrade cycle continues.
• For PFE, treat the news as strategic-option value rather than near-term earnings impact; incremental interest is positive, but not enough for a standalone long unless you are explicitly underwriting external innovation/BD optionality over 12+ months.
• Use WFC / OPY as a secondary read-through only if you want to express analyst-flow momentum; the better expression is still the underlying equity, not the broker names, because the market is rewarding data-follow-through more than target revisions.